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Background: Progression of chronic myelogenous leukemia (CML) is frequently accompanied by cytogenetic
evolution, commonly unbalanced chromosomal changes, such as an extra copy of Philadelphia chromosome (Ph), +8,
and i(17)(q10). Balanced chromosomal translocations typically found in de novo acute myeloid leukemia occur
occasionally in CML, such as inv(3)/t(3;3), t(8;21), t(15;17), and inv(16). Translocations involving the 11q23, a relatively
common genetic abnormality in acute leukemia, have been seldom reported in CML. In this study, we explored the
prevalence and prognostic role of 11q23 in CML.
Methods: We searched our pathology archives for CML cases diagnosed in our institution from 1998 to present.
Cases with 11q23 rearrangements were retrieved. The corresponding clinicopathological data were reviewed.
Results: A total of 2,012 cases of CML with available karyotypes were identified. Ten (0.5%) CML cases had 11q23
rearrangement in Ph-positive cells, including 4 cases of t(9;11), 2 cases of t(11;19), and 1 case each of t(2;11), t(4;11),
t(6;11), and t(4;9;11). Eight cases (80%) had other concurrent chromosomal abnormalities. There were 6 men and 4
women with a median age of 50 years (range, 21–70 years) at time of initial diagnosis of CML. 11q23 rearrangement
occurred after a median period of 12.5 months (range, 0–172 months): 1 patient in chronic phase, 2 in accelerated
phase, and 7 in blast phase. Eight of ten patients died after a median follow-up of 16.5 months (range, 8–186 months)
following the initial diagnosis of CML, and a median of 6.7 months (range, 0.8–16.6 months) after the emergence of
11q23 rearrangement. The remaining two patients had complete remission at the last follow-up, 50.2 and 6.9 months,
respectively. In addition, we also identified a case with 11q23/t(11;17) in Ph-negative cells in a patient with a history of
CML. MLL involvement was tested by fluorescence in situ hybridization in 10 cases, and 7 cases (70%) were positive.
Conclusions: In summary, chromosomal rearrangements involving 11q23 are rare in CML, frequently occurring in blast
phase, and are often associated with other cytogenetic abnormalities. These patients had a low response rate to
tyrosine kinase inhibitors and a poor prognosis.
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BCR-ABL1 derived from t(9;22)(q34;q11), its variant
translocations, or cryptic fusions is the sole chromo-
somal abnormality in about 80–90% of chronic mye-
logenous leukemia (CML) diagnosed in chronic phase
(CP). BCR-ABL1 signaling is believed to be the driving
force in CML pathogenesis, leading to disease progres-
sion and secondary genetic changes. Continuous BCR-
ABL1 activity induces DNA damage and inhibits DNA
repair, leading to genetic instability and clonal evolution
[1,2]. Clonal evolution, manifested by cytogenetics and
mutational changes, occurs in 5–10% of patients diag-
nosed in chronic phase, approximately 30% of patients
in accelerated phase (AP), and 50–80% of patients in
blast phase (BP) [2,3]. A recent study demonstrated that
the pattern of cytogenetic changes during clonal evolu-
tion remains similar in CML patients treated with or
without tyrosine kinase inhibitors (TKIs), supporting the
idea of genetic instability induced by BCR-ABL1 as the
mechanism of clonal evolution[4]. The most common
chromosomal aberrations during clonal evolution are
unbalanced chromosomal changes, including + Ph, +8,
i(17)(q10), and +19 [4], which are the so-called “major
route” abnormalities. Reciprocal translocations are much
less common and represent “minor route” abnormalities.
Several rearrangements typically occurring in de novo
acute myeloid leukemia (AML) and conferring prognos-
tic value, such as inv(3)(q21q26)/t(3;3)(q21;q26), t(8;21)
(q22,q22), t(15;17)(q22;q21), and inv(16)(p13q22), have
been infrequently observed as secondary cytogenetic
changes during clonal evolution of CML. Reciprocal
rearrangements involving 11q23 are extremely rare in
CML and until now only about ten cases in the form of
single case reports are available in the literature [5-14].
The clinicopathological characteristics and prognostic
value of 11q23 translocations in CML have not been
studied systematically.
Rearrangements involving 11q23/MLL locus are fre-
quently encountered in acute leukemia. About 70%–80%
of infant acute leukemia has 11q23/MLL abnormalities,
associated with a distinct genetic profile and poor prog-
nosis [15,16]. In adults, about 3%–4% of de novo AML
carries 11q23 translocations [17]. Rearrangements invol-
ving 11q23/MLL are also observed in therapy-related
AML, especially after topoisomerase inhibitor treatment.
The translocation partners for 11q23 are diverse, and
over 70 fusion partners have been characterized at the
molecular level to date [18]. The most common translo-
cations involving 11q23/MLL include t(9;11)(p22;q23),
t(4;11)(q21;q23), and t(11;19)(q23;p13) [18,19]. Although
the mechanisms of MLL-induced leukemogenesis seem
diverse and are not fully understood, most MLL gene re-
arrangements juxtapose the amino terminal portion of
MLL with the carboxyl terminal portion of its partners,resulting in chimeric oncoproteins [20]. Gene-expression
profiling studies demonstrated that MLL fusion proteins
induce leukemic transformation, at least in part, through
activation of homeobox genes, such as HOXA5 and
HOXA9 [21]. A recent study demonstrated that MLL-
AF6 fusion oncogene derived from t(6;11)(q27;q23) can
induce aberrant activation of RAS and its downstream
targets [22].
In this study, we aimed to explore the incidence,
pathology, and clinical features of CML cases with
11q23 rearrangement.
Results
Incidence and clinical characteristics
A total of 2,012 cases of CML with karyotypes were
identified in our pathology database and from this
group, 10 cases (0.5%) carried translocations involving
the 11q23 locus in Ph-positive cells. There were six men
and four women with a median age of 50 years (range,
21–70 years) at the time of initial diagnosis of CML. All
patients received therapies following CML diagnosis. De-
pending on the time of CML diagnosed, different regimens
were given; historically with IFNa, and more recently with
TKIs, including first-generation TKI imatinib and second-
generation TKIs dasatinib and nilotinib (Table 1). In con-
trast to cases 1–10, case 11 was a 48-year-old male with the
emergence of 11q23 translocation in Ph-negative cells.
Emergence of 11q23 rearrangement in Ph-positive cells
Rearrangement involving 11q23 developed after a median
period of 12.5 months (range, 0–172 months) following
the initial diagnosis of CML (Table 1). It was detected in
one patient (case 1) in CP, in two patients (cases 2 and 3)
in AP, accompanied with other AP features including in-
creased blast counts and thrombocytopenia; both were
transformed to BP during targeted therapy with TKIs,
after 1.6 and 12 months, respectively. The remaining eight
patients (cases 4–10) had 11q23 rearrangement in BP; two
patients (cases 5 and 6) presented as BP with 11q23
rearrangements at the initial diagnosis of CML. Both
cases showed small hypolobated “dwarf” megakaryocytes.
In addition, case 5 presented with basophilia (8%) and
eosinophilia (4%). These features support the diagnosis of
BP of CML instead of de novo AML with t(9;22). The
other six cases developed 11q23 rearrangements during
the course of CML treatment.
Emergence of 11q23 rearrangement in Ph-negative cells
In case 11, the 11q23 translocation developed in
Ph-negative cells. The patient was initially diagnosed
with CML in CP, with t(9;22)(q34;q11) as a sole ab-
normality. He was treated with imatinib, nilotinib, and
dasatinib. The patient showed a partial response to the
treatment. Thirty-two months after the original CML
Table 1 Clinicopathological features of CML with 11q23 translocation







1 F/64 Imatinib 17 CP (1% blasts) Yes Yes Yes 68 50.2 Alive
2 M/43 IFNa, Imatinib,
Dasatinib
172 AP (12% blasts) Yes No No 186 13.9 Dead
3 M/67 IFNa, Hydroxyurea 17 AP (12% blasts) Yes No N/A 33 16.6 Dead
4 F/50 IFNa 7 BP Yes No No 8 0.9 Dead
5 M/70 None 0 BP Yes Yes Yes 7 6.9 Alive
6 M/31 None 0 BP Yes NK NK 8 8 Dead
7 F/21 Hydroxyurea,
Imatinib
12 BP Yes No No 21 9.5 Dead
8 M/47 Hydroxyurea,
Imatinib
13 BP Yes No No 16 2.4 Dead
9 M/59 Hydroxyurea,
IFNa, Imatinib
13 BP No 14 0.8 Dead
10 F/50 Hydroxyurea, IFNa 12 BP No 17 5.3 Dead
11 M/48 Nilotinib, Imatinib,
Dasatinib
32 BP No 36 4.1 Dead
CCyR complete cytogenetic response, MMR major molecular response, N/A not available, NK not known as the patient had concurrent chemotherapy with
daunorubincin and ara-C.
aAge at initial diagnosis of CML.
bInitial treatments before 11q23 emergence.
cInterval (month) between CML diagnosis and 11q23 appearance.
dCML phase in which 11q23 developed.
eTKI treatment after 11q23 clonal evolution.
fTime (month) from CML diagnosis to the last follow-up.
gTime (month) from 11q23 emergence to the last follow-up.
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cytogenetics: 46,XY,t(11;17)(q23;q25) [20]. No Philadelphia
chromosome was identified, and fluorescence in situ
hybridization (FISH) for BCR-ABL1 was negative.
Emergence of 11q23 rearrangement in a CML case that
initially presented as myeloid sarcoma
In case 4, the patient initially presented with a breast
mass that was diagnosed as myeloid sarcoma with
t(9;22). The status of peripheral blood and bone marrow
at that time was unknown. The patient was treated with
IFNa. Three months later, bone marrow showed CML in
AP, and the patient was treated with idarubicin and ara-
C with a brief remission. Another 4 months later, the
patient showed massive and diffuse lymphadenopathy
with hepatosplenomegaly. A lymph node biopsy showed
myeloid sarcoma. Bone marrow biopsy showed acute
leukemia with a mixed myeloid/T phenotype (Table 2).
The conventional cytogenetics of this bone marrow
showed t(2;11)(q32;q23) in Ph-positive cells (Table 3).
Morphology and immunophenotype
Of ten cases with blast transformation in this study
(cases 2–11), nine showed myeloid, and one (case 4)
showed a mixed lineage (myeloid/T) immunophenotype
(Table 2). Several cases expressed lymphoid markers:case 10 expressed CD10 and CD22 while case 2 had par-
tial CD19. The blast morphology was heterogeneous and
some cases have monocytic differentiation (Figure 1 and
Table 2). CD64, a monocytic marker, was expressed in
six cases.
Cytogenetic data
The translocation partners for 11q23 were diverse and
included four cases of t(9;11), two cases of t(11;19), and
one case each of t(2;11), t(4;11), t(6;11), t(11;17), and
t(4;9;11) (Table 3). In a case of t(9;11) (case 6), t(11;18)
(q23;q11.2) and t(9;18)(p22;q11.2) were present, which
indicates a three-way translocation (Table 3). Besides
11q23, 8 of 11 cases had additional cytogenetic abnor-
malities, including − Y, i(17)(q10), inv(3)(q21q26.2), etc.
FISH studies to evaluate MLL gene status were per-
formed in ten cases. Seven cases showed MLL rearrange-
ment, whereas three cases had an intact MLL gene using
a commercially available breakapart probe.
Treatment and prognosis after emergence of 11q23
Eight patients (case 1–8) received TKI therapy, and
three of them (cases 5–7) also received allogeneic stem
cell transplant following TKI therapy. The list of TKIs
treatment was case 1 with nilotinib, case 2 with nilotinib
and bosutinib, case 3 with imatinib, case 4 with imatinib,
Table 2 Immunophenotype of blasts in CML with 11q23 translocations
# Lineage Blast Immunophenotype
2 Myeloid 60% +: CD7, CD19 partial, CD13, CD33, CD34, CD38, HLA-DR, MPO
−: CD2, CD3, CD5, CD10, CD14, CD15, CD20, CD41, CD56, CD64, CD117, TdT
3 Myeloid 58% +: CD13, CD33, CD38, CD64, HLA-DR, MPO (cytochemistry)
−: CD2, CD3, CD7, CD10, CD19, CD20, CD34, CD117,
4 Myeloid/T 60% +: CD3(c), CD5, CD7, CD13, CD33, CD34, CD43, CD117, TdT, MPO
−: CD10, CD19, CD20
5 Myeloid 64% +: CD4 partial, CD7 partial, CD13, CD15 subset, CD33, CD38, CD64, CD123, HLA-DR, MPO
−: CD2, CD3, CD5, CD10, CD14, CD19, CD22, CD34, CD36, CD41, CD56, CD117, TdT
6 Myeloid 80% +: CD11c, CD13, CD33, CD34 weak, CD38, CD43, CD64, CD117, HLA-DR, MPO
−: CD3, CD19
7 Myeloid 47% (PB) +: CD13, CD33, CD34 partial, CD38, CD64, CD117, HLA-DR, MPO
−: CD2, CD3, CD5, CD7, CD10, CD14, CD15, CD19, CD20, CD41, TdT
8 Myeloid 98% +: CD13, CD33, CD34 partial, CD38, CD117, HLA-DR, MPO (3% by cytochemistry)
−: CD2, CD5, CD7, CD10, CD14, CD19, CD20, CD41, CD64, TdT
9 Myeloid 81% +: CD7, CD13, CD33, CD34, CD38, CD64, CD117, MPO, TdT
−: CD2, CD3, CD10, CD19, CD20, HLA-DR
10 Myeloid 50% +: CD10, CD13, CD22 (c), CD33, CD34, CD38, HLA-DR, TdT partial
−: CD2, CD3, CD19, CD41, CD64, CD117, MPO
11 Myeloid 36% +: CD4, CD13, CD15, CD33, CD34 partial, CD38, CD64, CD117, CD123, MPO
−: CD2, CD3, CD5, CD7, CD14, CD19, CD22, CD36, CD56, HLA-DR, TdT
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case 7 with nilotinib, and case 8 with dasatinib. The
remaining patients (case 9–11) received conventional
chemotherapy targeting to acute leukemia.
In patients with 11q23 rearrangements in Ph-positive
cells, two patients achieved complete cytogenetic response
and major molecular response after TKI treatment; one
patient (case 1) had 11q23 as the sole secondary abnor-
mality and the other patient (case 5) had 11q23 at initial
CML diagnosis. These two patients were alive at the lastTable 3 Karyotypes and MLL FISH in CML with 11q23 translo
Case # Karyotypes




5 46,XY,t(9;22)(q34;q11.2) [16] /46,sl,t(9;11)(p22;q23),i(17)(q10) [16]/47
6 46,XY,t(9:22)(q34;q11.2) [9] /46,XY,der(9)t(9;18)(p22;q11.2),t(9;22)(q34
der(22)t(9;22) [11]
7 46,XX,t(9;22)(q34;q11.2) [7] /46,XX,der(4)t(4;9;11)(p12;p22;q23),der(9)
8 50,XY,t(9;11)(p22;q23),t(9;22)(q34;q11.2),+13,+17,+22,+der(22)t(9;22)
9 45,X,-Y,t(9;11)(p21;q23),t(9;22)(q34;q11.2) [8] /51,idem,+X,+6,+8,+21
10 46,XX,t(9;22)(q34;q11),t(11;19)(q23;p13) [15] /46,XX [4]
11 46,XY,t(11;17)(q23;q25) [20]follow-up, 50.2 and 6.9 months after 11q23 emergence.
The rest of the patients (8/10) died at the last follow-up,
at a median of 16.5 months (range, 8–186 months) fol-
lowing the initial diagnosis of CML and a median of
6.7 months (range, 0.8–16.6 months) following emergence
of the 11q23 translocation. The patient with 11q23 re-
arrangement in Ph-negative cells (case 11) died 4.1 months
following emergence of 11q23 translocation.
Of the three patients who received allogeneic stem













Figure 1 Blast morphology in CML with 11q23, blast phase. (A) A case of acute leukemia without maturation (case 8). (B) A case of acute
leukemia with monocytic differentiation (case 7) (NSE: non-specific esterase).
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transplant. The other two patients (cases 6 and 7) had
no response to TKI treatment. Transplant was per-
formed after induction chemotherapy. Both patients had
relapsed disease shortly after transplant and died at the
last follow-up.
Discussion
Although frequently encountered in AML and acute
lymphoid leukemia (ALL), 11q23 rearrangement occurs
very rarely in CML, in less than 1% of cases in this study
by conventional karyotype. The translocation partners
for 11q23 are diverse with t(9;11) (p22;q23) being the
most common. Most cases developed 11q23 transloca-
tion in BP, and were often associated with other chromo-
somal changes. Patients had a low response rate to TKI
treatment, and the overall survival was poor.
Clonal evolution with additional chromosomal ab-
normalities besides t(9;22) is considered as a feature of
disease progression in CML. The predominant emer-
gence of 11q23 in BP (8/11) suggests that 11q23/MLL
may play a direct role in CML blast transformation. In
AML and ALL, the role of MLL in leukemic transforma-
tion has been extensively studied. Although the fusion
partners for MLL are diverse with more than 70 fusion
partners described, most MLL rearrangements join the
N-terminal region of MLL with C-terminal portion of its
partners, forming chimeric oncoproteins [21]. Although
the mechanisms of MLL-induced leukemia are complex
and not fully understood, the chimeric proteins have
been shown to induce HOX expression, which can block
hematopoietic differentiation and induce leukemia [20].
Whether MLL plays a similar role in CML blastic trans-
formation needs further confirmation.
The prognostic significance of clonal evolution in
CML is variable and depends on many factors, including
the particular type of cytogenetic changes, the time and
phase of emergence of clonal evolution, other con-
current chromosomal abnormalities, the presence orabsence of other AP features, and treatment regimens.
In the era of pre-TKI therapy, INFa induced a complete
suppression of clonal evolution in 46% of patients with
only Ph chromosome and/or diploid karyotype present
after resolution of clonal evolution. About 7% of patients
with clonal evolution achieved a complete cytogenetic
remission on INFa therapy, and the absence of other AP
features was associated with a better response [23]. With
the first generation of TKI, imatinib, one study showed
that clonal evolution had no significant effect on achie-
ving major or complete cytogenetic response, but it was
a poor prognostic factor for survival in both CP and AP
[24]. Another study showed that clonal evolution was as-
sociated with lower cytgenetic response rate in patients
in AP with other signs of acceleration [25]. For patients
on second generation of TKI therapy, cases with clonal
evolution but without other features of AP had similar
hematologic/cytogenetic response and overall survival to
cases in CP without clonal evolution. However, when
other features of AP were present, the presence of clonal
evolution adversely affected overall survival [26].
As mentioned above, the prognostic significance of
clonal evolution also depends on the specific type of
chromosomal changes. Fabarius et al. reported that the
major route, not minor route cytogenetic aberrations at
initial diagnosis, had a negative prognostic impact on
CML patients [27]. Consistently, a recent study indicated
that trisomy 8, chromosome 17 abnormalities, and com-
plex cytogenetic changes carried worse prognosis than
others [26]. Accordingly, in European LeukemiaNet rec-
ommendations, the major routes, not the minor routes
of chromosomal abnormalities, are defined as one of
criteria for AP [28]. Although 11q23 abnormalities are
considered as “minor route” abnormalities, they appear
to carry a poor prognosis. In our cohort, nine patients
(9/11) died at the last follow-up. The majority of cases
had 11q23 abnormalities in BP(8/11). Only one patient
(case 1) had 11q23 in CP, in the absence of other AP fea-
tures. This patient achieved complete cytogenetic response
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Two patients (cases 2 and 3) had 11q23 in AP, accompan-
ied with other AP features including increased blast count
and thrombocytopenia. These two cases showed poor re-
sponse to TKI therapy and transformed to blast phase after
a period of 1.6 and 12 months.
Interestingly, not all cases with 11q23 rearrangements
showed MLL involvement by FISH analysis. In our series,
30% (3/10) cases showed negative MLL rearrangement by
FISH study using a commercialMLL breakapart probe. Al-
though not frequent, similar findings had been described
in CML and other myeloid neoplasms. Giurliano et al. re-
ported two cases of myeloid neoplasms (AML and atypical
CML) with cytogenetic changes involving 11q23 but with
intact MLL gene by FISH: one with t(3;11)(q21;q23) and
another with t(6;11)(q15;q23) [29]. Cox et al. studied 378
adult acute leukemia cases and found that in 18 cases with
rearrangements involving 11q22-25 bands by conventional
karyotyping, only 11 had MLL gene involvements [30]. In
CML, two cases with 11q23 rearrangements but intact
MLL were previously reported. One case had t(2;11)(p21;
q23) [12] and the other had t(4;11)(q21;q23) [5]. In our
study, three patients showed 11q23 translocations by con-
ventional cytogenetics but were negative for MLL involve-
ment by FISH, including t(2;11)(q32;q23) (case 4), t(4;11)
(q21;q23) (case 1), and t(6;11)(p11.2;q23) (case 2). The
exact mechanisms and roles of 11q23+/MLL− in leukemia
are unknown. We proposed two potential mechanisms
here. First, although MLL gene appeared intact in these
cases, MLL gene may be controlled and dysregulated by
other promoters or enhancers as a result of translocations.
Secondly, other genes at the 11q23 locus may play roles in
leukemogenesis, such as FLI1 [31,32]. Future molecular
study to identify the breakpoints of these 11q23+/MLL−
translocations and their fusion partner is needed.
In case 11, although the patient initially presented with
chronic phase CML and responded to TKI, he later deve-
loped blast transformation with 11q23 translocation. FISH
for BCR-ABL1 was negative. The development of acute
leukemia in Ph-negative clones is intriguing. The occur-
rence of chromosomal changes in Ph-negative cells is less
common than in Ph-positive cells, and the significance of
this phenomenon is not fully understood [33]. Jabbour
et al. analyzed 258 CML patients in CP with imatinib
therapy [34]. After a median follow-up of 37 months, 9%
patients developed chromosomal abnormalities in Ph-
negative cells, with −Y and trisomy 8 being the most
common. Others included del (7), del (20), t(11;17), etc. Al-
though similar cytogenetic changes are associated with
myelodysplastic syndromes, these cytogenetic abnormalities
in CML seem transient and most disappeared after a me-
dian of 5 months. Development of MDS or acute leukemia
is extremely rare in Ph-negative cells. In a study of 1,701
CML patients, Kovitz found that 3 patients developedAML and MDS in Ph-negative cells [35]. Monosomy 7 and
complex cytogenetic changes were the most common
chromosomal abnormalities in reported cases of MDS/
AML developed in Ph-negative cells [36-40]. In our case,
the patient developed AML in Ph-negative cells carrying
11q23/MLL abnormality. To our best knowledge, this is the
first case of acute leukemia developing in Ph-negative cells
with 11q23/MLL involvement. The mechanisms behind the
development of chromosomal abnormalities in Ph-negative
cells are not clear, but it is less likely due to TKI therapy
[34]. A plausible explanation is that t(9;22) is not a random
event, but rather develops from a preceding genetic abnor-
mality, which occurs at the level of hematopoietic stem
cells. This genetic abnormality not only induces t(9;22) but
also other chromosomal abnormalities. During CML treat-
ment, cells with t(9;22) are eradicated and cells with other
chromosomal abnormalities emerge [41].
Two patients (cases 5 and 6) presented with acute
leukemia with t(9;22) and 11q23 rearrangements at time
of initial diagnosis. This timing raised the question of
whether they were de novo AML or BP of CML.
Features that favor the latter include the presence of
i(17)(q10) and “dwarf” megakaryocytes; both are more
frequently seen in CML cases. Also in case 5, the patient
had basophilia and eosinophilia, a phenomenon more
often encountered in CML.
As mentioned above, occasional case reports of CML
with 11q23 translocations are available in the literature.
The fusion partners previously reported for 11q23 in
CML include 1q21 [10], 2p21 [12], 4q21 [5], 6q25 [7],
9p22 [11,8,6], 17q21 [9], 19p13.1 [14], and 19p13.3 [13].
In our study, 9p21-22/AF9 was the most common partner
for 11q23. In addition, we identified several new fusion
partners for 11q23 in CML: 2q32, 6p11.2, 17q25, and
18q11.2. Of these, t(11;17)(q23;q25) potentially involves
the SEPT9 gene on 17q25 and had been reported in AML
and myelodysplastic syndrome with a poor prognosis [42],
whereas t(2;11)(q32;q23), t(6;11)(p11.2;q23), and t(11;18)
(q23;q11.2) translocations have never been previously de-
scribed in the literature. It will be of interest to explore
and characterize the potential genes involved in these re-
ciprocal translocations and their roles in leukemia.
In conclusion, 11q23 translocations are rare events in
CML, frequently occurring in blast phase and associated
with a poor prognosis. Not all 11q23 translocations
involve MLL gene. We described a first case of acute
leukemia developed in Ph-negative cells with 11q23/MLL
involvement. Several novel genetic loci are identified as
fusion partners for 11q23.
Materials and methods
Case selection, histologic and clinical review
We searched the pathology archives of our institution
from 1998 to the present for cases of CML with available
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were reviewed to identify cases with 11q23 translocations.
Other genetic changes involving 11q23, such as del(11)q23,
were not included in this study. Biopsy and smear slides
were retrospectively reviewed. The corresponding medical
records were reviewed to obtain clinical data, including
age, sex, disease progression, treatment regimens, re-
sponse to therapy, and follow-up data.
Cytogenetic studies
Conventional chromosomal analysis was performed on
G-banded metaphase cells prepared from unstimulated
24- and 48-h BM aspirate culture using standard me-
thods. Twenty metaphases were analyzed and the results
were reported using the International System for Human
Cytogenetic Nomenclature (ISCN 2013). FISH for MLL
gene rearrangement was conducted on BM culture cells
or direct aspirate smears using MLL dual color, break-
apart probe (Abbott Molecular, Inc.) according to the
standard protocols.
Definition of cytogenetic and molecular response
Complete cytogenetic response is defined as 0% Ph-positive
metaphases using conventional cytogenetics analysis of at
least 20 metaphases. Major molecular response is defined
as more than 3-log reduction of BCR-ABL mRNA.
BCR-ABL1 transcript measurement
BCR-ABL1 and ABL1 transcript levels were detected
simultaneously and quantitative results expressed as the
ratio of BCR-ABL1 to ABL levels.
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